Halozyme Thrp Stock Price, News & Analysis

Merus (Nasdaq: MRUS) and Halozyme (Nasdaq: HALO) announced a global non-exclusive collaboration and license agreement on November 17, 2025 to develop a subcutaneous formulation of petosemtamab using Halozyme's ENHANZE® drug delivery technology.

Merus licensed ENHANZE® for development and potential commercialization of petosemtamab, an EGFR x LGR5 bispecific antibody that is in clinical studies for multiple solid tumors including recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). Terms include an upfront payment, potential commercial and sales-based milestone payments, and low‑mid single digit royalties on net sales of the ENHANZE®-formulated product.

Halozyme (NASDAQ: HALO) announced on November 7, 2025 that Johnson & Johnson received FDA approval of DARZALEX Faspro (daratumumab and hyaluronidase-fihj) co-formulated with ENHANZE as a single-agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM). DARZALEX Faspro is described as the first and only approved treatment for HR-SMM, enabling earlier intervention before progression to active multiple myeloma.

The approval was based on the Phase 3 AQUILA study (NCT03301220) comparing DARZALEX Faspro to active monitoring. The release notes ~36,000 estimated U.S. multiple myeloma diagnoses in 2025, ~15% classified as smoldering, and an estimated 50% of HR-SMM patients progress within two years.

Halozyme (NASDAQ: HALO) priced two convertible note offerings: $650 million 0% notes due Feb 15, 2031 (2031 Notes) and $650 million 0.875% notes due Nov 15, 2032 (2032 Notes), with initial purchaser options of up to an additional $100 million for each series. Each series has an initial conversion rate equal to approximately $87.20 per share (about a 27.5% premium to the $68.39 close on Nov 6, 2025). Net proceeds are expected to be approximately $1.274 billion (or ~$1.47 billion if options exercised). The company expects to use about $182.7 million to fund capped call transactions and about $1.020 billion to repurchase outstanding 2027 and 2028 convertible notes, with an expected closing on Nov 12, 2025.

Halozyme (NASDAQ: HALO) announced a proposed offering of $650 million principal of convertible senior notes due 2031 and $650 million principal of convertible senior notes due 2032, with initial purchaser options of up to $100 million additional for each series.

The notes will be senior unsecured, accrue interest semi-annually, and mature Feb 15, 2031 and Nov 15, 2032. Conversions may be settled in cash and, at the company's election, shares of common stock. The company plans capped call transactions and expects to use proceeds for capped calls, repurchases of existing 2027 and 2028 convertible notes, and general corporate purposes.

Halozyme (NASDAQ: HALO) reported record Q3 2025 results with total revenue $354.3M (22% YoY) and royalty revenue $236.0M (52% YoY). GAAP net income was $175.2M and GAAP diluted EPS was $1.43; adjusted EBITDA was $248.2M. The company raised 2025 guidance to $1.30–1.375B total revenue, $850–880M royalties, $885–935M adjusted EBITDA, and $6.10–6.50 non-GAAP diluted EPS.

Halozyme announced a planned $750M upfront acquisition of Elektrofi with up to three $50M regulatory milestones and a CFO transition plan; share repurchases used $92.3M to buy ~1.7M shares YTD. Cash and marketable securities were $702.0M on Sept 30, 2025.

Halozyme (NASDAQ: HALO) will release its third quarter 2025 financial and operating results on Monday, November 3, 2025 following the close of trading.

The company will host a conference call on Monday, November 3, 2025 at 1:30 p.m. PT / 4:30 p.m. ET to discuss results. The call requires pre-registration via the provided link and a live webcast and replay will be available in the Investors section of Halozyme's website.

Halozyme (NASDAQ: HALO) has announced a definitive agreement to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments. The acquisition centers on Elektrofi's breakthrough Hypercon™ technology, enabling biologic formulations with 400-500 mg/ml concentrations - up to 5 times higher than current standards.

The strategic acquisition expands Halozyme's drug delivery capabilities with long-term IP protection into the 2040s. Two of Elektrofi's partners are expected to begin clinical development of Hypercon™ formulated products by end of 2026, with royalty revenue projected to start in 2030. The transaction is expected to close in Q4 2025 and will be less than 5% dilutive to Non-GAAP EPS over medium-term.

Halozyme reaffirmed its 2025 guidance with total revenue of $1,275-$1,355 million and royalty revenue of $825-$860 million.

Halozyme Therapeutics (NASDAQ: HALO) announced its participation in three upcoming investor conferences in September 2025. CEO Dr. Helen Torley and VP of Investor Relations Tram Bui will represent the company.

The schedule includes presentations at the Wells Fargo Healthcare Conference in Boston on September 4, the Morgan Stanley Global Healthcare Conference in New York on September 8, and the H.C. Wainwright Global Investment Conference in New York on September 9. Live audio webcasts will be available on Halozyme's website with 90-day replay access.

Halozyme (NASDAQ: HALO) reported exceptional Q2 2025 results with total revenue increasing 41% YOY to $326 million and royalty revenue growing 65% YOY to $206 million. Net income surged 77% YOY to $165 million, while adjusted EBITDA rose 65% YOY to $226 million.

The company raised its 2025 guidance, projecting total revenue of $1,275-$1,355 million (26-33% YOY growth) and adjusted EBITDA of $865-$915 million (37-45% YOY growth). Growth was driven by three blockbuster therapies: DARZALEX SC, Phesgo, and VYVGART Hytrulo.

Halozyme announced its third $250 million share repurchase tranche under the $750 million authorized plan, completing $303 million in share repurchases during Q2 2025.